AngioChem Demonstrates Peptide Antibody Conjugate That Successfully Crosses The Blood Brain Barrier And Increases Survival In HER-2 Positive Brain Tumors

MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its peptide-antibody conjugate, ANG4043 successfully crosses the BBB, reduces tumor size and significantly increases survival in mice with intracranial HER2-positive brain tumors. These results underscore the potential for development of novel antitumor therapeutics for neuro-oncology indications. The data presentation revealed that the company’s technology has been successfully applied to monoclonal antibodies (mAbs) for creation of brain-penetrant antibody conjugates of anti-Human Epidermal Growth Factor Receptor 2 (HER2). The data was presented at the 2013 San Antonio Breast Cancer Symposium, held December 10-14, 2013 in San Antonio, TX.

Help employers find you! Check out all the jobs and post your resume.